letrozole + cyclophosphamide

Letrozole + cyclophosphamide is a combination therapy consisting of letrozole, an aromatase inhibitor, and cyclophosphamide, an alkylating agent. This regimen is primarily investigated and used in the treatment of hormone receptor-positive breast cancer, particularly in postmenopausal women. Letrozole works by inhibiting the enzyme aromatase, thereby reducing estrogen production and limiting the growth stimulus for estrogen-dependent tumors. Cyclophosphamide acts as a cytotoxic agent that crosslinks DNA strands, leading to apoptosis of rapidly dividing cells. When administered together—often with metronomic (low-dose continuous) scheduling—this combination has demonstrated synergistic effects on tumor cell cytotoxicity and apoptosis beyond what either drug achieves alone. The regimen has shown promising results as neoadjuvant or primary systemic therapy in elderly patients with breast cancer[1][2][3][6].

Other names

metronomic cyclophosphamide + letrozoleoral cyclophosphamide + letrozole